UK’s Cystic Fibrosis Trust Appoints First-Ever “Director Of Impact”
The Cystic Fibrosis Trust recently announced its first-ever appointment of a “Director of Impact” to spearhead the organization’s commitment to improve care, support and research for those with CF in the United Kingdom.
Dr. Keith Brownlee boasts a proven record of experience and expertise as a cystic fibrosis specialist pediatrician, having worked for more than 20 years at the Leeds General Infirmary. As the Trust’s new Director of Impact, he will play a crucial role in leading the organization in maximizing the impact of health services for those suffering with cystic fibrosis, as well as offering leadership toward helping the Trust achieve its strategic ambitions.
The Cystic Fibrosis Trust is the only national charity in the UK committed to supporting those with this life-shortening genetic disease. Cystic fibrosis affects both the lungs and the digestive system.
Commenting on his new role, Dr. Bownlee stated in a press release: “This role is both professional and personal to me. It is an honour to be given the opportunity to help lead the Trust in reaching its ambitions aims to improve and transform the lives of people with CF and their families. I hope to harness the vast opportunities available through science to deliver more targeted treatments, better care and ensure that people with CF and their families are put at the heart of everything we do. Crucially, we cannot do it alone. I hope that I will be able to bring together everyone who is involved in and affected by cystic fibrosis to stand with us to one day beat cystic fibrosis for good.”
The Trust’s Chief Executive, Ed Owen, added: “I am delighted Keith is joining the Trust at this time. He brings great experience and understanding of cystic fibrosis from his clinical work, and remains much loved by many of those he cared for and their families. “His insight and expertise will be an enormous asset as the Trust rolls out its ambitious plans to improve and transform the lives of people with cystic fibrosis. He will also play an important role in enhancing our vital partnership with cystic fibrosis clinicians and health professionals during this period of opportunity and change.”
The Cystic Fibrosis Trust also plays a key role as a national charity that funds research into the disease and provides information and support for patients and families. Recentl, the Trust announced that the nonprofit organization will begin using DocuSign technology for Digital Transaction Management in order to eliminate printing, faxing, scanning and overnighting documents in completing transactions, enabling more concentrated focus on its core mission — finding a cure for Cystic Fibrosis (CF). DocuSign Impact Digital Transaction Management (DTM) empowers nonprofits like Cystic Fibrosis Trust to automate manual, paper processes to help their charities increase staff productivity, while continuing to meet security and compliance needs, and to reduce costs while improving staff, donor and volunteer experience.
